Men fared better under surveillance, while women benefited more from targeted therapies for the treatment of chronic ...

Ravi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.